Goldman Sachs Reinstates Buy on Tarsus Pharmaceuticals, Announces $116 Price Target
Tarsus Pharmaceuticals Inc TARS
$75.69
▼ -0.36%
($-0.27)
Open
$75.78
Prev Close
$75.96
Day Range
$73.85 – $76.17
52W Range
$53.89 – $91.53
Market Cap
$3.54B
Beta
0.34
EPS (TTM)
$-1.08
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-10-16 |
| Shares Out. | 43,020,000 |
| Website | tarsusrx.com/ ↗ |
| Phone | 13025310855 |
| Employees | 370 |
| Revenue | $173.9M |
| Gross Profit | $161.8M |
| Net Income | -$18.6M |
| Free Cash Flow | $56.0M |
| Total Assets | $611.1M |
| Total Liabilities | $264.4M |
| Equity | $346.7M |
About Tarsus Pharmaceuticals Inc
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
Tarsus Pharmaceuticals Inc is a publicly traded company under the ticker symbol TARS on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
14 analysts (2026-09-01)